Thymalfasin
As of the edition of 20 October 2026, Thymalfasin is a protein: marketed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Protein
- Brand name
- Zadaxin
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- SciClone Pharmaceuticals
- Registered trials
- 46, 4 stopped early
- Disease areas
- Cancer; Digestive system; Infections; Lungs and airways; Blood and lymph; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 3 | 4 | 0 |
| Phase 1 | 3 | 2 | 1 | 0 |
| Phase 2 | 22 | 7 | 5 | 4 |
| Phase 3 | 7 | 4 | 2 | 0 |
| Phase 4 | 6 | 2 | 0 | 0 |
| All trials | 46 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| sigma-tau i.f.r | Lead sponsor of trials | 2002 to now |
| Replicor | Lead sponsor of trials | 2011 to now |
| SciClone Pharmaceuticals | Lead sponsor of trials | 2016 to now |